Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17508808 | 0.90 | TRPC5 (0.82) | TRPC5USP1 | |
| SCHEMBL17508805 | 0.87 | TRPC5 (0.77) | TRPC5USP1 | |
| SCHEMBL17508456 | 0.84 | TRPC5 (1.00) | TRPC5USP1 | |
| SCHEMBL17509027 | 0.83 | TRPC5 (0.71) | TRPC5USP1 | |
| SCHEMBL17523188 | 0.82 | TRPC5 (0.84) | TRPC5 | |
| SCHEMBL17546575 | 0.81 | TRPC5 (0.83) | TRPC5 | |
| SCHEMBL17508807 | 0.81 | TRPC5 (1.00) | TRPC5 | |
| SCHEMBL17508411 | 0.80 | TRPC5 (1.00) | TRPC5 | |
| SCHEMBL17523166 | 0.76 | TRPC5 (0.61) | TRPC5USP1 | |
| SCHEMBL17508418 | 0.75 | TRPC5 (1.00) | TRPC5USP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220031706-A1 | TRPC ION CHANNEL INHIBITORS FOR USE IN THERAPY | UNIVERSITY OF LEEDS (GB) | 2022-02-03 | — | — | US | disclosed |
| US-20200345741-A1 | TRPC ION CHANNEL INHIBITORS FOR USE IN THERAPY | UNIVERSITY OF LEEDS (GB) | 2020-11-05 | — | — | US | disclosed |
| EP-3180337-B1 | PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES INC (US) | 2018-10-10 | — | — | EP | disclosed |
| EP-3180337-A1 | PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | Hydra Biosciences, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9440973-B2 | Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440973-B2 | Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440973-B2 | Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| WO-2016023825-A1 | PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016023825-A1 | PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20160039815-A1 | PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160039815-A1 | PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160039815-A1 | PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345741-A1 | TRPC ION CHANNEL INHIBITORS FOR USE IN THERAPY | TRPC1, TRPC7, TRPC4 | TRPC5 6/4885USP1 4539/4885 |
| US-20220031706-A1 | TRPC ION CHANNEL INHIBITORS FOR USE IN THERAPY | TRPC1, TRPC7, TRPC4 | TRPC5 6/4885USP1 4539/4885 |
| US-20160039815-A1 | PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | TRPC5, P2RX5, HTR5A | TRPC5 1/4885USP1 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.